STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [Form 4] HALOZYME THERAPEUTICS, INC. Insider Trading Activity

Halozyme (HALO) COO exercises 21,546 options and sells 28,857 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported an exercise-and-sell transaction in company stock. On March 9–10, 2026, she exercised options to acquire a total of 21,546 shares of common stock at an exercise price of $33.51 per share.

Over the same two days, she conducted open-market sales totaling 28,857 shares of common stock at weighted average prices around $67.64–$68.25, with specific trades executed in price ranges disclosed in the footnotes. Following these transactions, she directly holds 7,055 shares of common stock and retains 67,678 options to purchase common stock.

Positive

  • None.

Negative

  • None.
Insider Caudill Cortney
Role SVP, CHIEF OPERATING OFFICER
Sold 28,857 shs ($1.96M)
Type Security Shares Price Value
Exercise Option to Purchase Common Stock 1,546 $33.51 $52K
Exercise Common Stock 1,546 $33.51 $52K
Sale Common Stock 8,857 $67.64 $599K
Exercise Option to Purchase Common Stock 20,000 $33.51 $670K
Exercise Common Stock 20,000 $33.51 $670K
Sale Common Stock 17,900 $67.751 $1.21M
Sale Common Stock 2,100 $68.252 $143K
Holdings After Transaction: Option to Purchase Common Stock — 67,678 shares (Direct); Common Stock — 15,912 shares (Direct)
Footnotes (1)
  1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Caudill Cortney
(Last) (First) (Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CHIEF OPERATING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/09/2026 M 20,000 A $33.51 34,366 D
Common Stock 03/09/2026 S 17,900 D $67.751(1) 16,466 D
Common Stock 03/09/2026 S 2,100 D $68.252(2) 14,366 D
Common Stock 03/10/2026 M 1,546 A $33.51 15,912 D
Common Stock 03/10/2026 S 8,857 D $67.64(3) 7,055 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock $33.51 03/09/2026 M 20,000 (4) 11/01/2033 Common Stock 20,000 $33.51 69,224 D
Option to Purchase Common Stock $33.51 03/10/2026 M 1,546 (4) 11/01/2033 Common Stock 1,546 $33.51 67,678 D
Explanation of Responses:
1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did HALO (Halozyme Therapeutics) report for Cortney Caudill?

Halozyme’s COO Cortney Caudill exercised options and sold shares on March 9–10, 2026. She exercised 21,546 options at $33.51 per share and sold 28,857 common shares in open-market trades at weighted average prices in the high-$60s.

How many Halozyme (HALO) shares did the COO sell and at what prices?

Cortney Caudill sold 28,857 Halozyme common shares in open-market transactions. The reported weighted average sale prices were about $67.64–$68.25 per share, with detailed price ranges for each trade disclosed in the accompanying footnotes.

How many Halozyme (HALO) options did the COO exercise in this Form 4?

The filing shows Cortney Caudill exercised options for 21,546 shares of Halozyme common stock. These options carried an exercise price of $33.51 per share and were part of a grant that vests over four years from a November 1, 2023 grant date.

What are Cortney Caudill’s Halozyme (HALO) holdings after these transactions?

After the reported March 9–10, 2026 activity, Cortney Caudill directly holds 7,055 shares of Halozyme common stock. She also retains 67,678 options to purchase additional common shares according to the post-transaction balances disclosed in the Form 4.

Were the Halozyme (HALO) COO’s sales under a Rule 10b5-1 trading plan?

The Form 4 footnotes describe weighted average sale prices and price ranges but do not state that the trades were executed under a Rule 10b5-1 trading plan. The disclosure focuses on pricing details and option grant vesting terms.

What does the option vesting schedule look like for Halozyme (HALO) COO grants?

The options referenced were granted on November 1, 2023. They vest over four years, with 25% vesting after 12 months from the grant date and the remaining shares vesting in equal monthly installments of 1/48th of the option shares thereafter.